NeuroVive Pharmaceutical AB organizacji Current ratio
Jaka jest wartość Current ratio organizacji NeuroVive Pharmaceutical AB?
Wartość Current ratio organizacji NeuroVive Pharmaceutical AB to 8.14
Jaka jest definicja Current ratio?
Wskaźnik bieżącej płynności to wskaźnik płynności, który określa, czy firma ma wystarczające zasoby, aby wywiązać się z zobowiązań krótkoterminowych.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio firm w Miscellaneous sektor na LSE w porównaniu do NeuroVive Pharmaceutical AB
Czym się zajmuję organizacja NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Firmy z current ratio podobne do NeuroVive Pharmaceutical AB
- Wartość Current ratio organizacji Shine Box Capital to 8.12
- Wartość Current ratio organizacji Manchester & London Investment Trust Plc to 8.12
- Wartość Current ratio organizacji Castle Biosciences to 8.12
- Wartość Current ratio organizacji Parkway Minerals NL to 8.12
- Wartość Current ratio organizacji Fission 3.0 to 8.13
- Wartość Current ratio organizacji Westgrund AG to 8.13
- Wartość Current ratio organizacji NeuroVive Pharmaceutical AB to 8.14
- Wartość Current ratio organizacji RAPT Therapeutics to 8.14
- Wartość Current ratio organizacji LPL Inc to 8.14
- Wartość Current ratio organizacji Pinetree Capital to 8.15
- Wartość Current ratio organizacji Spectra Products to 8.15
- Wartość Current ratio organizacji UroGen Pharma Ltd to 8.15
- Wartość Current ratio organizacji Tak Lee Machinery to 8.15